[summit leader] Li Yingji: how to identify the cardiotoxicity of compounds in the early stage and reduce the risk of new drug development

Doctor of science of Jilin University, doctor of cardiovascular medicine of Justus Liebig University Giessen of Germany, general manager of Beijing AISI Yipu Biotechnology Co., Ltd., "Haiju Engineering" Beijing special expert The combination of these titles is Li Yingji's exclusive label Behind these labels is a scientific researcher who has been quietly studying and has been focusing on cardiovascular electrophysiology and pharmacology for many years Dr Li is devoted to cardiovascular system pharmacology, cardiac safety pharmacology and ion channel drug screening, and has rich practical experience in the evaluation of cardiac safety related to QT interval prolongation From September 8 to 10, the 2017 China Pharmaceutical Summit Forum and the list of top 100 pharmaceutical enterprises' R & D strength jointly sponsored by yaozhi.com and China Pharmacy magazine co opened in Chongqing We are honored to invite Dr Li to bring you a feast of knowledge and technology sharing about "comprehensive pre clinical cardiac safety evaluation of Xiaofen antineoplastic drugs" After graduating from Bethune Medical University in 1994, Li Yingji became a cardiologist and received a master's degree in internal medicine from China Medical University In 2000, Li Yingji entered the school of basic medicine of Jilin University and obtained his Ph.D in science In 2003, Li Yingji studied in the Institute of cardiovascular medicine of Justus Liebig University Giessen, Germany, and obtained his Ph.D in medicine with full merit In June 2010, Li Yingji returned home from Austria to start his own business and founded Beijing aisiyipu Biotechnology Co., Ltd., which is the first domestic enterprise dedicated to the research and development of ion channel related drug contracts, and also the pioneer of ion channel drug research in China Dr Li is an expert in cardiac ion channel research, mainly engaged in cardiac safety pharmacology, antiarrhythmic drug screening and mechanism of action research He has his own unique opinions on drug screening related to ion channel, and is good at the establishment of various ion channel drug screening methods such as NAV, CAV, BKCa, KCNQ, trpv, TRPC, GABA, etc At the same time, it has some achievements in the study of the mechanism of pulmonary high-pressure ion channel and the drug screening of traditional Chinese medicine and natural chemical products The cardiotoxicity of drugs is an important reason for the failure of new drug research and development Therefore, S7A and S7B issued by ICH put forward the guiding principles of "core battery" and "non clinical evaluation of cardiac QT interval extension" The common cardiotoxicity of antitumor drugs includes arrhythmia, coronary syndrome, heart failure, hypertension, etc., so how to identify the cardiotoxicity of compounds early is very important to avoid the risk of new drug development From September 8 to 10, 2017 China Pharmaceutical Industry Summit Forum and the list of top 100 pharmaceutical companies in R & D strength was released We have an appointment with Dr Li Yingji in Chongqing Please look forward to it! Some articles published by Dr Li Yingji are recommended as follows: Li Y, Connolly m, Nagaraj C par β / δ, the actual signaling factor in prostacyin induced Purmonary vasation Am J respir cell mol 2012 Mar; 46 (3): 372-9 2 Tang, B; Li, y; Nagaraj, C endotherin-1 innovations background two point domain channel TASK-1 in primary human Purmonary artry smooth muscle Cells Am J Respir Cell Mol Biol 2009 3.Olschewski, A; Li, Y; Tang, B Impact of TASK-1 in human pulmonary artery smooth muscle cells CIRC RES 2006; 98(8): 1072-1080 4.Olschewski, A; Schnoebel-Ehehalt, R; Li, Y; Tang, B; Bräu, ME; Wolff, M Mexiletine and lidocaine suppress excitability of dorsal horn neurons Anesthesia & Analgesia.